Nasdaq

GE HealthCare Introduces Next-Generation SIGNA MRI Technology

(RTTNews) - GE HealthCare (GEHC) announced the submission of its next-generation SIGNA™ MRI technology to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The new systems are designed ...
Nasdaq

GE HealthCare Receives FDA Clearance for Head-Only SIGNA MAGNUS 3.0T MRI System

New MRI technology aims to advance neuroimaging and biomarker research CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) has received FDA 510(k) clearance for its innovative SIGNA™ MAGNUS,i a ...
Business Wire

Imricor Collaborates with GE HealthCare in Interventional Cardiac MRI

MINNEAPOLIS--(BUSINESS WIRE)--Imricor Medical Systems, Inc. (ASX:IMR) Imricor, the global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation products, is pleased to announce ...
Hosted on MSN

GE HealthCare bolsters MRI provision with icometrix acquisition

GE HealthCare has entered an agreement to acquire AI-based brain imaging company icometrix to expand its magnetic resonance (MR) imaging capabilities for neurological disorders. The imaging giant ...
Business Wire

GE HealthCare Announces Completion of Phase I Subject Recruitment in Early Clinical Development Program for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

Novel manganese-based macrocyclic Magnetic Resonance Imaging (MRI) agent could offer an alternative to gadolinium-based agents Manganese is a trace element naturally occurring in, and efficiently ...
Morningstar

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation ...

Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agents A manganese-based MRI contrast agent could ...